Bio-Rad Laboratories Inc (BIO)

522.20
-1.12(-0.21%)
After Hours
522.20
0.00(0.00%)
- Real-time Data
  • Volume:
    217,556
  • Day's Range:
    511.69 - 534.74
  • 52 wk Range:
    468.86 - 832.70

BIO Overview

Prev. Close
523.32
Day's Range
511.69-534.74
Revenue
2.9B
Open
526.14
52 wk Range
468.86-832.7
EPS
-4.88
Volume
217,556
Market Cap
15.55B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
230,688
P/E Ratio
-
Beta
0.89
1-Year Change
-12.72%
Shares Outstanding
29,941,606
Next Earnings Date
Aug 04, 2022
What is your sentiment on Bio-Rad Labs?
or
Market is currently closed. Voting is open during market hours.

Bio-Rad Laboratories Inc News

  • Bio-Rad Labs Tops Q1 EPS by $1.54
    • ByInvesting.com-

    Bio-Rad Labs (BIO) reported Q1 EPS of $4.94, $1.54 better than the analyst estimate of $3.40. Revenue for the quarter came in at $700 million versus the consensus estimate of...

  • Bio-Rad Laboratories Up 7% After Investor Day
    • ByInvesting.com-

    By Sam BougheddaInvesting.com -- Bio-Rad Laboratories Inc (NYSE:BIO), the life science and clinical diagnostic products firm gave an optimistic forecast at its investor day on...

Bio-Rad Laboratories Inc Analysis

Bio-Rad Laboratories Inc Company Profile

Bio-Rad Laboratories Inc Company Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralNeutral
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyBuySell
  • Going to drop by shrinking rev and eps
    0
    • Sold before the crazy beat..
      0
      • Massively undervalued!
        0
        • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
          0
          • Incredible earnings! Come on in now
            0
            • To the moon!!!!!
              0
              • ATTENTION! READ HERE "As of August 2020, Bio-Rad had 37% ownership of Sartorius, and shares of Sartorius have increased about a hundredfold since Bio-Rad first invested in the company in 2003. In the early 2000s, Bio-Rad continued increasing its share of Sartorius, and has booked large (unrealized) gains on the investment since that time. With the Sartorius stake accounting for approximately half of the firm’s valuation, the investment has generated significant value for shareholders. We believe this is relevant in an evaluation of Bio-Rad’s stewardship, as current CEO Norman Schwartz has led the company since 2003, the year of the first investment in Sartorius, and oversaw the increase of the investment in subsequent years."  Morningstar
                0
                • underestimated stock
                  0